From research collaborations to changes to drug development, pharma will have to find new ways of working to discover Covid-19 treatments.
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Silence has received an important validation, but making progress could be tough.
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.